GALT

Galectin Therapeutics Stock Price

2.55
-0.20 (-7.27%)
Upgrade to Real-Time
Afterhours (Closed)
2.55

Low
1.82

52 Week Range

High
5.70

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Galectin Therapeutics Inc GALT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.20 -7.27% 2.55 19:25:17
Open Price Low Price High Price Close Price Prev Close
2.78 2.61 2.78 2.66 2.75
Bid Price Ask Price Spread News
2.55 2.65 0.10 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,443 256,402 $ 2.66 $ 681,649 - 1.82 - 5.70
Last Trade Time Type Quantity Stock Price Currency
19:26:40 1 $ 2.65 USD

Period:

Draw Mode:

Galectin Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 148.14M 58.09M 23.51M $ - $ - -0.40 -6.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.94M 22.40%

more financials information »

Galectin Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GALT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.602.942.522.78411,802-0.05-1.92%
1 Month3.374.402.523.406,423,761-0.82-24.33%
3 Months4.074.572.523.492,557,201-1.52-37.35%
6 Months2.185.701.823.152,394,4190.3716.97%
1 Year2.705.701.823.121,329,122-0.15-5.56%
3 Years5.716.981.503.46665,211-3.16-55.34%
5 Years1.529.490.493.44619,0011.0367.76%

Galectin Therapeutics Description

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.


Your Recent History
NASDAQ
GALT
Galectin T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.